Granular necrosis: a distinctive form of cell death in malignant tumours.

Carcinoma granular necrosis high grade necrosis pathogenesis prognosis sarcoma

Journal

Pathology
ISSN: 1465-3931
Titre abrégé: Pathology
Pays: England
ID NLM: 0175411

Informations de publication

Date de publication:
Aug 2020
Historique:
received: 15 05 2020
revised: 11 06 2020
accepted: 11 06 2020
pubmed: 21 6 2020
medline: 4 6 2021
entrez: 21 6 2020
Statut: ppublish

Résumé

Foci of necrosis are frequently seen in malignant tumours and may be due to a variety of causes. Different types of necrosis are given various names based upon their morphological features and presumed pathogenesis, such as coagulative, liquefactive and fibrinoid necrosis. Here, we propose the term 'granular necrosis' (GN) for a specific form of tumour necrosis characterised by the presence of well-defined necrotic foci being sharply demarcated from adjacent viable tumour. A constant feature is loss of architecture resulting in an amorphous necrotic mass containing granular nuclear and cytoplasmic debris, without an associated neutrophilic infiltrate. There is usually extensive karyorrhexis, which in larger tumours is more prominent at the periphery. These foci are often microscopic but may range up to several millimetres or larger in size. This distinctive form of necrosis has been erroneously given a variety of names in the literature including coagulative necrosis and microscopic necrosis, which on the basis of the aforementioned gross and microscopic findings is inappropriate. It is apparent that this is a specific form of necrosis, hence the descriptive term 'granular necrosis' that differentiates this form of necrosis from other types. The presence of GN is recognised as occurring in a variety of tumour types, being commonly seen in renal cell carcinoma, where it has been shown to have independent prognostic significance. In some epithelial and stromal tumours of the uterus, the presence of GN also has prognostic significance and is a defining feature for the differentiation of uterine leiomyoma and leiomyosarcoma. The pathogenesis of GN is unresolved. It does not show the features of apoptosis and in recent studies has been shown to have some of the molecular changes associated with necroptosis.

Identifiants

pubmed: 32561208
pii: S0031-3025(20)30840-0
doi: 10.1016/j.pathol.2020.06.002
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

507-514

Informations de copyright

Copyright © 2020. Published by Elsevier B.V.

Auteurs

Hemamali Samaratunga (H)

Aquesta Uropathology and University of Queensland, Brisbane, Qld, Australia.

Brett Delahunt (B)

Department of Pathology and Molecular Medicine, Wellington School of Medicine and Health Sciences, University of Otago, Wellington, New Zealand. Electronic address: brett.delahunt@otago.ac.nz.

John R Srigley (JR)

Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.

Daniel M Berney (DM)

Department of Molecular Oncology, Queen Mary University Hospital, London, United Kingdom.

Liang Cheng (L)

Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.

Andrew Evans (A)

Department of Laboratory Information Support Systems, University Health Network, Toronto, ON, Canada.

Bungo Furusato (B)

Department of Pathology, Nagasaki University Graduate School of Biomedical Sciences and Cancer Genomics Unit, Clinical Genomics Center, Nagasaki University Hospital, Sakamoto, Nagasaki, Japan.

Katia R M Leite (KRM)

Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, Brazil.

Gregory T MacLennan (GT)

Department of Pathology and Urology, Case Western Reserve University, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.

Guido Martignoni (G)

Department of Pathology and Diagnostics, School of Medicine and Surgery, University of Verona, Verona, Italy.

Holger Moch (H)

University and University Hospital Zurich, Department of Pathology and Molecular Pathology, Zurich, Switzerland.

Chin-Chen Pan (CC)

Department of Pathology, Taipei Veterans General Hospital, Taipei, Taiwan.

Gladell Paner (G)

Departments of Pathology and Surgery (Section of Urology) University of Chicago, Chicago, IL, USA.

Jae Ro (J)

Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Weill Medical College of Cornell University, Houston, TX, USA.

Michelle Thunders (M)

Department of Pathology and Molecular Medicine, Wellington School of Medicine and Health Sciences, University of Otago, Wellington, New Zealand.

Toyonori Tsuzuki (T)

Department of Surgical Pathology, Aichi Medical University, School of Medicine, Nagakute, Japan.

Thomas Wheeler (T)

Department of Pathology and Laboratory Medicine, Baylor St Luke's Medical Center and Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX, USA.

Theodorus van der Kwast (T)

Department of Pathology, Princess Margaret Cancer Center, University Health Network, Toronto, ON, Canada.

Murali Varma (M)

Department of Cellular Pathology, University Hospital of Wales, Cardiff, UK.

Sean R Williamson (SR)

Department of Pathology, Cleveland Clinic, Cleveland, OH, USA.

John W Yaxley (JW)

Department of Medicine, University of Queensland, Wesley Urology Clinic, Royal Brisbane and Womens Hospital, Brisbane, Qld, Australia.

Lars Egevad (L)

Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH